LAE 104
Alternative Names: LAE-104Latest Information Update: 03 Oct 2022
At a glance
- Originator Laekna Therapeutics
- Class Antifibrotics; Hepatoprotectants; Recombinant fusion proteins
- Mechanism of Action Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hepatic fibrosis
Highest Development Phases
- Preclinical Hepatic fibrosis
Most Recent Events
- 14 Sep 2022 LAE 104 is available for licensing as of 14 Sep 2022. https://www.laekna.com/ (Laekna Therapeutics pipeline, September 2022)
- 14 Sep 2022 Laekna Therapeutics has patent pending for LAE 104 worldwide
- 14 Sep 2022 Preclinical studies in Hepatic fibrosis in China (Parenteral) prior to September 2022